GlassScriptPhysician profile
Philip J Elbaum
NPI 1235484031
$11,748.75
in general payments reported to CMS, 2019-2025
39 companies · $1,677 in 2025
The $1,677 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,038 · 2020: $415 · 2021: $842 · 2022: $1,227 · 2023: $1,836 · 2024: $4,715 · 2025: $1,677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,417 · Consulting Fee: $2,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,417.16 |
| Consulting Fee | $2,810.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Medical Systems Corporation | $2,810.00 | 2024 | |
| Abbvie INC. | $2,232.37 | 2019-2025 | |
| Janssen Biotech, INC. | $1,287.36 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $782.08 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $680.15 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $581.16 | 2019-2024 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $378.32 | 2022-2025 | Dupixent |
| Gilead Sciences, INC. | $375.44 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $340.96 | 2019-2025 | Ocaliva |
| Qol Medical, LLC | $268.21 | 2020-2024 | Sucraid, Sucraid |
| Ardelyx, INC. | $257.75 | 2023-2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $220.64 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $181.66 | 2022-2025 | |
| Ferring Pharmaceuticals INC. | $146.18 | 2021-2025 | Rebyota, Clenpiq |
| Phathom Pharmaceuticals, INC. | $133.02 | 2024-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $119.03 | 2019-2025 | |
| Madrigal Pharmaceuticals | $111.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $94.48 | 2019 | |
| Lilly USA, LLC | $82.83 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $72.20 | 2022-2024 | Injectafer |
| Nestle Healthcare Nutrition INC. | $64.31 | 2021-2023 | |
| Fresenius Kabi USA, LLC | $61.84 | 2023 | Idacio |
| Redhill Biopharma INC. | $59.10 | 2021-2022 | |
| Celltrion USA INC. | $50.66 | 2025 | Vegzelma |
| Shionogi INC | $44.00 | 2019 | |
| Mallinckrodt Hospital Products INC. | $41.60 | 2022-2024 | Terlivaz |
| Aimmune Therapeutics, INC. | $41.53 | 2024 | |
| Braintree Laboratories, INC. | $34.76 | 2022 | |
| Ironwood Pharmaceuticals, INC | $27.63 | 2020-2021 | |
| Grifols USA, LLC | $27.12 | 2024 | Xembify |
| Novo Nordisk INC | $19.34 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $19.26 | 2024 | Monoferric |
| Recordati_rare_diseases_inc. | $19.22 | 2025 | Panhematin |
| Organon LLC | $17.03 | 2025 | Hadlima, Renflexis |
| Orphalan INC | $15.12 | 2025 | Cuvrior |
| Teleflex LLC | $14.25 | 2024 | Solesta |
| Boston Scientific Corporation | $14.08 | 2024 | Exalt Model D |
| Merck Sharp & Dohme LLC | $11.69 | 2020 | |
| Ucb, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Elbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.